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Diabetes in spontaneously hypertensive rats is associated with cortical renal GLUT1 and GLUT2 overexpression. Our objective
was to evaluate the effect of the angiotensin-converting enzyme blockade on cortical renal GLUT1 and GLUT2 expression,
urinary albumin and urinary TGF-β1. Streptozotocin, 50 mg/kg, or citrate buffer (N = 16) was administered as a single injection
into the tail vein in adult spontaneously hypertensive rats (~260 g). Thirty days later, these diabetic spontaneously hypertensive
rats received ramipril by gavage: 0.01 mg·kg-1·day-1 (D0.01, N = 14), 1 mg·kg-1·day-1 (D1, N = 9) or water (D, N = 11) for 15 days.
Albumin and TGF-β1 (24-h urine), direct arterial pressure, renal tissue angiotensin-converting enzyme activity (fluorometric
assay), and GLUT1 and GLUT2 protein levels (Western blot, renal cortex) were determined. Glycemia and glycosuria were
higher (P < 0.05) in the diabetic rats compared with controls, but similar between the diabetic groups. Diabetes in spontaneously
hypertensive rats lowered renal tissue angiotensin-converting enzyme activity (40%), which was reduced further when higher
ramipril doses were used. Diabetes associated with hypertension raised GLUT1 by 28% (P < 0.0001) and GLUT2 by 76% (P =
0.01), and both doses of ramipril equally reduced cortical GLUT1 (D vs D1 and vs D0.01, P ≤ 0.001). GLUT2 levels were reduced
in D0.01 (P < 0.05 vs D). Diabetes increased urinary albumin and TGF-β1 urinary excretion, but the 15-day ramipril treatment
(with either dose) did not reduce them. In conclusion, ramipril is effective in lowering renal tissue angiotensin-converting enzyme
activity, as well as blocking cortical GLUT1 overexpression, which may be beneficial in arresting the development of diabetic
nephropathy.
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Introduction
Diabetic nephropathy is the leading cause of renal
failure in patients starting renal replacement therapy. The
two main strategies for its prevention are to improve glyce-
mic control and to lower blood pressure, especially by
applying angiotensin-converting enzyme (ACE) inhibitors.
The renoprotective effects of ACE inhibitors are believed
to be independent of their reduction of systemic blood
pressure (1) because of their specific effect in lowering
intraglomerular pressure (2) and effects resulting from
angiotensin II (AII) blockage.
Angiotensin II can be deleterious by causing systemic
and intraglomerular hypertension and also by an effect on
mesangial cells by directly stimulating their production of
transforming growth factor-β1 (TGF-β1) (3). Elevated pro-
duction and/or activity of TGF-β1 in the kidney is a final
common mediator of diabetic renal hypertrophy and mes-
angial matrix expansion (4). Mesangial stretch, induced by
hypertension (5) and by hyperglycemia (6), can also in-
crease TGF-β1 production. Moreover, in diabetic rats high
glucose itself may increase mesangial AII generation in-
creasing TGF-β1 expression (3). We demonstrated that
urinary TGF-β1 is increased simultaneously with high
GLUT1 and GLUT2 protein in the renal cortex of the
streptozotocin (STZ)-induced diabetic rat (7).
Renal glucose reabsorption is a coordinated process,
which takes place in the epithelial cells of the proximal
tubule, involving two classes of glucose transporters, the
Na+-glucose transporters (SGLTs) and facilitative diffusion
transporters (GLUTs) (8). In the early S1 segment, where
the bulk of filtered glucose is reabsorbed, the low affinity/
high capacity glucose transporters, SGLT2 and GLUT2
are co-expressed in the luminal brush border membrane
and in the basolateral membrane, respectively. Increases
in the cortical GLUT2 gene expression have been exten-
sively reported in diabetes (9-15), and are important for
renal glucose reabsorption maintenance in this condition,
since high blood and interstitial glucose concentrations
may lower the outwardly directed glucose gradient from
tubule to blood (11). GLUT1 protein is also detected in the
outer renal cortex, where it is not related to the tubule
epithelial cells, but to the mesangial cells (16). It has been
suggested that increased expression of cortical GLUT1
(mesangial cells) (7) and GLUT2 (S1 tubular cells) (14) is
involved in the development and progression of diabetic
nephropathy.
Subsequently, upregulation of cortical renal GLUT1
and GLUT2 levels and increased urinary TGF-β1 and
albumin excretion in genetically hypertensive diabetic rats
have been reported (17). The major effect of hypertension
on GLUT1 overexpression could be mediated by AII, since
it is elevated in the plasma of stroke-prone spontaneously
hypertensive rats (SHR; 18) and, in vitro, it causes overex-
pression of GLUT1 in vascular smooth muscle (19) and in
mesangial cells (20). The well-known diabetes-induced
GLUT2 overexpression (9,21,22) and the further rise that
hypertension can determine in it (17) may promote, in
addition to hyperglycemia, a further elevation in the inter-
stitial renal glucose concentration, and more glucose is
taken up by mesangial cells through GLUT1. However, the
role of AII on the GLUT1 and GLUT2 overexpression of
SHR has not yet been explored.
An ACE-inhibitor used at low doses (non-anti-hyper-
tensive) could facilitate the evaluation of the beneficial
effects of these drugs, independent of their anti-hyperten-
sive effect. Low doses of quinapril and ramipril were used
before, and can effectively block the renin-angiotensin
system (23). There is currently no report in the literature
showing the effects of the inhibition of the renin-angio-
tensin system upon cortical renal GLUT1 and GLUT2
expression in vivo. Thus, we investigated whether the
treatment of diabetic hypertensive rats with ramipril could
modulate GLUT1 and GLUT2 expression.
Material and Methods
Experiments were performed on 2-month-old male SHR
(Animal House of the Coordenação de Produção e Experi-
mentação Animal, Fundação Estadual de Produção e
Pesquisa em Saúde, Porto Alegre, RS, Brazil), weighing
~260 g, acclimatized for 1 week, fasted overnight and
rendered diabetic (D) by a single injection of STZ (50 mg/
kg, Sigma Chemical Co., USA) into the tail vein. STZ was
dissolved in citrate buffer, pH 4.5, and injected slowly.
Non-diabetic rats (C) were injected with citrate buffer.
Diabetes was defined as a non-fasting glucose >250 mg/
dL in tail vein blood 48 h after STZ injection. The animals
were maintained for 30 days in individual cages with free
access to tap water and standard rat chow. They were
then treated for 15 days with a low dose of ramipril (0.01
mg·kg-1·day-1, D0.01; N = 21), a high dose of ramipril (1
mg·kg-1·day-1, D1; N = 18) or water (C: N = 23 and D: N =
20), administered daily by gavage. Before and after this
treatment, 24-h urine was collected in metabolic cages for
glucose, albumin and TGF-β1 analyses.
In 50 rats (C: N = 16; D: N = 11; D0.01: N = 14; D1:
N = 9), catheters (PE-10) filled with saline were im-
planted under anesthesia into the femoral artery for
direct measurement of arterial pressure. One day later,
the cannula was connected to a strain-gauge trans-
ducer (P23Db, Gould-Statham, USA) and arterial pres-
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sure signals were recorded for 20 min using a micro-
computer with an analog-to-digital converter board (CO-
DAS, 2-kHz sampling frequency, Dataq Instruments,
Inc., USA). The rats were conscious and moved freely
during the experiments. Recorded data were analyzed
on a beat-to-beat basis. One day later, the animals
were anesthetized with sodium pentobarbital (25 mg/
kg body weight, iv) and their kidneys removed for meas-
urement of ACE activity.
Thirty-two rats (C: N = 7; D: N = 9; D0.01: N = 7; D1: N
= 9) had their kidneys removed for GLUT1 and GLUT2
protein content (45 days of diabetes, 15 days after ramipril
or placebo treatment). They were anesthetized with so-
dium pentobarbital (25 mg/kg body weight, iv), their kid-
neys were perfused with Hanks’ buffer, to eliminate the
intravascular blood content, and removed. Renal outer
cortex and outer medulla were dissected and the tissue
fragments of each area (1.5 mm slices) were weighed and
frozen at -70°C for further analysis.
The experimental protocol was approved by the Ethics
Committee for Animal Research of Instituto de Cardiologia
do Rio Grande do Sul, and the studies were conducted in
accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals (http://
dels.nas.edu/ilar_n/ilarhome/).
Glucose, albumin and TGF-β1
Glycemia was evaluated 48 h and 45 days after STZ/
citrate buffer injection (test strips, Advantage, Roche, USA).
Urinary glucose was measured using the colorimetric en-
zymatic test (commercial kit, Merck, Germany, Centrifichem
System 400-Roche/Cobas Mira-Roche).
Samples for the measurement of urinary albumin were
collected without preservatives and stored at -70°C after
centrifugation. Albuminuria was measured by a quantita-
tive direct competitive enzyme-linked immunosorbent as-
say (ELISA; Nephrat, Exocell Inc., USA) using a highly
specific anti-rat albumin antibody. The quantification range
for albuminuria was 0.156-10 mg/dL. Samples were di-
luted 1:10 (controls) and 1:2 (diabetics). Results are re-
ported as mg/24 h.
Urinary TGF-β1 was assayed by solid phase ELISA
(R&D Systems, UK). Urine samples were collected on
ice and centrifuged at 10,000 rpm for 30 min at 4°C.
Supernatant was removed and stored at -70°C. On the day
of the assay, samples (0.5 mL) were acidified to a pH
of 2-3 with 100 µL 1 N HCL for 10 min and then re-
neutralized to pH 7-8 with 100 µL 1.2 N NaOH/0.5 M
HEPES. Results are reported as ng/24 h. The mean intra-
and interassay coefficients of variation were 2.0 and 13.1%,
respectively.
Angiotensin-converting enzyme activity
ACE activity was determined using the fluorometric
assay (24). One kidney was quickly harvested, rinsed,
blotted and homogenized in 0.4 M sodium borate buffer,
pH 7.2. Supernatants from homogenized tissues (20 µL)
were incubated with 490 or 480 µL assay buffer containing
5 mM Hip-His-Leu in 0.4 M sodium borate buffer and 0.9 M
NaCl, pH 8.3, for 15 or 30 min at 37°C. The reaction was
stopped by the addition of 1.2 mL 0.34 M NaOH. The
product, His-Leu, was measured fluorometrically at 365-
nm excitation and 495-nm emission with a fluorescence
spectrometer (Shimadzu, RF 1501, Japan). o-Phthaldial-
dehyde (100 µL, 20 mg/mL) in methanol was added, and
after 10 min the solution was acidified with 200 µL 3 N HCl
and centrifuged at 3000 rpm for 10 min at room tempera-
ture. To correct for the intrinsic fluorescence of the tissues,
time zero blanks were prepared by adding tissue after
NaOH. The sensitivity of the assay was ≤0.02 nmol·mg
tissue-1·min-1; the fluorescence intensity was linear with
the concentration of His-Leu generated from 0.02 to 15
nmol·mg tissue-1·min-1. The results are reported as nmol
His-Leu·min-1·mg protein-1, measured with Bradford’s meth-
od (25) (bovine serum albumin as the standard).
GLUT1 and GLUT2
Renal cortex was analyzed for GLUT1 and GLUT2
protein content and renal medulla was analyzed for GLUT1
protein content. Anti-sera against GLUT1 and GLUT2 were
raised in male New Zealand rabbits, and have been suc-
cessfully used for immunoblotting (17,21).
The tissue samples were homogenized in 10 w/v buffer
(10 mM) Tris-HCl, 1 mM EDTA, and 250 mM sucrose, pH
7.4, containing 5 mg/mL aprotinin, and centrifuged at 3000
g for 15 min. The supernatant was centrifuged at 12,000 g
for 20 min, and the pellet was re-suspended as a plasma
membrane fraction, in which the 5' nucleotidase (plasma
membrane marker) and alkaline phosphatase (brush bor-
der membrane marker) activities were shown to be more
than six and three times increased, respectively, com-
pared with the enzyme activity in the supernatant of the
first centrifugation. Western blot analysis was then per-
formed as previously described (17,21). Briefly, equal
amounts of membrane protein (100 µg from medulla and
150 µg from cortex samples) were subjected to SDS-
PAGE (10%) and transferred by electrophoresis to nitro-
cellulose paper. After blocking with non-fat milk, the sheets
were incubated with the specific antiserum, followed by
washing and incubation with (125I)-protein A (Amersham
Pharmacia Biotech, UK). After a final wash, the nitrocellu-
lose sheets were dried at room temperature, and exposed
to an X-ray film for 5 days at -70°C. The blots were
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lar between the diabetic groups 45 days after STZ. There-
fore, no differences in these variables could be attributed
to different ramipril doses between groups.
The results concerning renal tissue ACE activity are
reported in Figure 1. Diabetes caused lower (40%) renal
tissue ACE activity levels compared with C (P < 0.001). As
expected, reduced ACE activity was also observed in the
ramipril-treated rats. ACE activity levels were progres-
sively lower as the dose of ACE inhibitor increased. Com-
pared to group D rats, renal tissue ACE activity was 59%
lower in group D1 rats (P < 0.0001).
All groups displayed high mean arterial pressure lev-
els, a characteristic of the animal model employed. Strep-
tozotocin did not affect mean arterial pressure, but ramipril
caused significantly lower (P < 0.05) mean arterial pres-
sure levels in D0.01 and D1 rats in comparison with D and
C rats (164 ± 6, 159 ± 5, 145 ± 5, and 137 ± 8 mmHg in C,
D, D0.01, and D1, respectively). Although the average
arterial pressure levels were apparently lower in the D1
rats, they were not statistically different from those in
D0.01 rats. Heart rate was similar between groups (386 ±
9, 359 ± 12, 370 ± 27, and 325 ± 21 bpm in groups C, D,
D0.01, and D1, respectively; P > 0.05)
quantified by measuring absorbance using the Image Mas-
ter ID® software (Pharmacia Biotech, Sweden). The results
were normalized considering the mean of the values of
control animals (SHR) in each membrane as 100, and
reported as arbitrary units.
Data analysis
Data are reported as means ± SEM. Statistical signifi-
cance was calculated by one-way ANOVA, and by the post
hoc Student-Newman-Keuls test. Urinary albumin and TGF-
β1 data were log-transformed before analysis. Statistical
significance was defined at the 0.05 level.
Results
Table 1 shows the characteristics of the rats studied.
Body weights were similar between groups at baseline.
Thirty and 45 days after the STZ injection, body weights
were lower in rats of groups D, D0.01, and D1 compared
with controls. Plasma and urinary glucose levels and uri-
nary volume were higher in the diabetic rats compared with
controls, showing the efficacy of the diabetes induction.
Weight, glycemia, urine volume, and glycosuria were simi-
Table 1. Characteristics of diabetic hypertensive rats treated with ramipril.
C (N = 16) D (N = 11) D0.01 (N = 14) D1 (N = 9)
Initial weight (g) 263 ± 5 265 ± 4 263 ± 4 264 ± 4
30-day weight (g) 302 ± 4 249 ± 7* 237 ± 8* 239 ± 7*
45-day weight (g) 316 ± 4 247 ± 7* 233 ± 8* 234 ± 8*
48-h glycemia (mg/dL) 111 ± 5 461 ± 17* 429 ± 15* 444 ± 19*
45-day glycemia (mg/dL) 96 ± 4 403 ± 23* 394 ± 25* 419 ± 19*
45-day glycosuria (mg/24 h) 1.1 ± 0.6 5191 ± 878* 6154 ± 679* 6031 ± 752*
45-day diuresis (mL/24 h) 12 ± 0.8 76 ± 5* 79 ± 4* 83 ± 5*
Data are reported as means ± SEM. C = control non-diabetic spontaneously hypertensive rats; D = diabetic spontaneously
hypertensive rats; D0.01 = diabetic spontaneously hypertensive rats treated with 0.01 mg/kg ramipril daily for 15 days; D1 = diabetic
spontaneously hypertensive rats treated with 1 mg/kg ramipril daily for 15 days. *P < 0.05 vs C (ANOVA and post hoc Student-
Newman-Keuls test).
Figure 1. Kidney angiotensin-converting enzyme (ACE) activity
in non-diabetic spontaneously hypertensive rats (C, N = 9) and
diabetic spontaneously hypertensive rats not treated with ramipril
(D, N = 10) or treated with ramipril 0.01 mg·kg-1·day-1 (D0.01, N
= 11) and 1 mg·kg-1·day-1 (D1, N = 10). Data are reported as
mean ± SEM. Different letters indicate statistically significant
differences between groups (P < 0.001, post hoc Student-New-
man-Keuls test).
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Table 2. Effect of diabetes and ramipril administration on rat urinary albumin and TGF-β1.
C (N = 16) D (N = 34)
30-day urinary albumin (mg/24 h) 33.0 (24.5-82.3) 148.0 (100.0-259.0)*
30-day urinary TGF-β1 (ng/24 h) 445.0 (397.5-566.8) 3056.0 (2083.8-3890.5)*
C (N = 16) D (N = 11) D0.01 (N = 14) D1 (N = 9)
45-day urinary albumin (mg/24 h) 43.0 (28.0-109.0) 147.5 (136.5-245.5)* 189.0 (161.3-310.3)* 183.0 (150.0-259.0)*
45-day urinary TGF-β1(ng/24 h) 451.0 (252.2-853.5) 3040.5 (2149.3-3155.0)* 2625.0 (1615.3-3903.3)* 3377.0 (2473.0-4988.0)*
Data are reported as median and 25-75%. TGF-β1 = transforming growth factor-β1;  C = control non-diabetic spontaneously hyperten-
sive rats; D = diabetic spontaneously hypertensive rats; D0.01 = diabetic spontaneously hypertensive rats treated with 0.01 mg/kg ramipril
daily for 15 days; D1 = diabetic spontaneously hypertensive rats treated with 1 mg/kg ramipril daily for 15 days. *P < 0.0001 vs C (Student
t-test for comparisons between 30-day data and ANOVA/post hoc Student-Newman-Keuls test for comparisons between 45-day data).
Albuminuria and urinary TGF-β1 30 days after the STZ
injection are reported in Table 2. Albuminuria increased by
3 times in group D rats (P < 0.0001), and urinary TGF-β1
excretion was 7.3 times higher (P < 0.0001) in the same
animals compared with controls. The evaluation performed
15 days after the ACE blockage with ramipril (45 days after
the STZ injection) indicated no change in albuminuria and
urinary TGF-β1 in relation to controls at the doses em-
ployed.
Figure 2A shows that diabetes caused higher (28%)
cortical GLUT1 expression in hypertensive rats (P < 0.0001).
Ramipril treatment reduced this effect significantly at both
Figure 2. Renal cortical GLUT 1 (panel A), GLUT 2 (panel B) and
renal medullary GLUT1 (panel C) protein determined by Western
blot analysis of samples taken from non-diabetic spontaneously
hypertensive rats (C, N = 7), diabetic spontaneously hyperten-
sive rats not treated with ramipril (D, N = 9), diabetic spontane-
ously hypertensive rats treated with 0.01 mg·kg-1·day-1 ramipril
(D0.01, N = 7), and diabetic spontaneously hypertensive rats
treated with 1 mg·kg-1·day-1 ramipril (D1, N = 9). Top, typical
autoradiograms; bottom, data reported as mean ± SEM. AU =
arbitrary units. Different letters indicate statistically significant
differences between groups (P < 0.05, post hoc Student-New-
man-Keuls test).
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doses employed, the levels of D1 rats being lower than that
observed in non-diabetic rats (D1 vs C, P < 0.05). How-
ever, there was no difference in cortical GLUT1 protein
expression induced by the different intensities of ACE
inhibition (D0.01 vs D1, P = 0.500). Figure 2B shows the
GLUT2 protein results. The association of diabetes with
hypertension caused a 76% increase in cortical GLUT2
content (P < 0.05). Ramipril normalized these levels in the
D0.01 group (D vs D0.01, P < 0.05; C vs D0.01, P = 0.89).
Surprisingly, high doses of the drug did not further de-
crease these levels; instead, cortical GLUT2 protein levels
of the D1 group were similar to those of the D group (D vs
D1, P = 0.91; C vs D1, P < 0.001). Medullary GLUT1
protein was similarly reduced by diabetes in the 3 diabetic
groups compared with C (D vs C and D0.01 vs C, P < 0.05;
D1 vs C, P < 0.01, Figure 2C).
Discussion
The major findings were: 1) diabetes in SHR caused a
decrease in renal tissue ACE activity, no reduction in mean
arterial pressure levels, but higher renal GLUT1 and GLUT2,
urinary albumin and TGF-β1 excretion; 2) 0.01 mg/kg
ramipril in the STZ-hypertensive rats decreased renal tis-
sue ACE activity, mean arterial pressure levels, renal
GLUT1 and GLUT2, but did not change urinary albumin
and TGF-β1 excretion; 3) 1 mg/kg ramipril induced lower
renal tissue ACE activity than the 0.01 mg/kg dose did, but
mean arterial pressure and GLUT1 reductions were similar
with both doses with no effect upon renal GLUT2 expres-
sion, urinary albumin or TGF-β1 levels. This is the first
study showing that the inhibition of ACE in the kidney can
down-regulate GLUT1 in the STZ-diabetic-hypertensive
rat.
The ramipril dose of 0.01 mg/kg did not affect arterial
pressure in non-diabetic SHR in a study by Linz et al. (23),
but lowered mean arterial pressure of diabetic animals in
our study. We hypothesize that the volume-depleted state,
characteristic of uncontrolled diabetes, allowed a depres-
sor effect of ramipril even at doses that are non-anti-
hypertensive in non-diabetic rats. Indeed, higher arterial
pressure response to NO-synthase inhibition (26) and to
chronic salt loading (27) was previously shown by us in
diabetic rats, compared with non-diabetic rats, possibly
related to volume-dependent and salt-sensitive mechan-
isms. Methodological problems (inadequacy of the admin-
istered doses) were discarded because we administered
ramipril by gavage and the renal tissue ACE activity clearly
distinguished the experimental groups.
Although there is evidence showing a positive relation-
ship between the development of hypertension and local
tissue ACE activity (28), in the present study diabetes and
hypertension in association lowered renal tissue ACE ac-
tivity, which has already been reported in STZ-diabetic
Wistar rats (29), STZ-diabetic SHR (30) and genetic mod-
els of diabetes (31). Moreover, higher doses of ramipril in
diabetic rats progressively lowered tissue ACE activity
even more, as was expected and shown before with other
drugs of the same class (32).
The additive effect of hyperglycemia and high arterial
pressure levels upon cortical GLUT1, GLUT2, albumin-
uria, and urinary TGF-β1 overexpression was previously
shown by us (17), and these findings were confirmed by
the present study. Stimulation of the matrix extracellular
protein synthesis by the mesangial cell in response to
increased cellular metabolism of glucose occurs as a
consequence of chronically increased interstitial concen-
tration of the substrate (4). GLUT1, the main glucose
transporter in these cells, has a low Km for glucose (~1
mM), thus, within the physiological glucose levels, the
glucose transport rate is already maximal. The only way by
which glucose transport rate may rise is by modulating the
amount of the glucose transporter (7,33). Overexpression
of GLUT2 intensifies tubular glucose reabsorption, leading
to higher interstitial concentrations of glucose, so that
more glucose is available to mesangial cells, GLUT1 over-
expression is induced, more glucose is taken up by the
mesangial cells and, finally, acceleration of the well-known
intracellular steps involved in the pathogenesis of diabetic
nephropathy occurs (9).
Concerning medullary GLUT1 levels, we showed be-
fore (17) that diabetes in SHR did not induce its well-
described effect of reducing medullary GLUT1 (7). How-
ever, in the present study, diabetes induced a significant
reduction of medullary GLUT1 in SHR, which may be
related to the longer duration and severity of hyperglyce-
mia. Moreover, neither ACE inhibition, nor arterial pres-
sure lowering affected the levels of this glucose trans-
porter, suggesting that at this site (medulla) the GLUT1
expression is controlled by other mechanisms, probably
related to the hyperglycemia, which was unchanged among
the diabetic groups.
There was a clear beneficial effect of cortical GLUT2
reduction induced by 0.01 mg/kg ramipril, but, surprisingly,
this effect was lost as animals received higher doses and
lower renal ACE was obtained. By treating the diabetic-
hypertensive rats with 1 mg/kg ramipril, GLUT2 levels
returned to the previous high levels, which even further
lowered renal tissue ACE activity. This indicates that the
GLUT2 modulation was not related to the lower arterial
pressure, but to the renin-angiotensin-system blockage
itself. In experimental diabetic nephropathy, it was already
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shown that low doses of ramipril - the same used in this
experiment - do not inhibit the urinary excretion of bradyki-
nin; however, high doses of the drug can definitely reduce
this kinin urinary excretion, thus increasing its concentra-
tion in the renal tissue (34). Considering that bradykinin is
involved in the ACE-induced β-adrenergic receptor up-
regulation (35), and that increased sympathetic activity
can increase renal GLUT2 expression (9), we hypothesize
that the reduced GLUT2 expression by ramipril was over-
balanced by increased sympathetic tissue activity when
high doses were used. The clear effect of 0.01 mg/kg
ramipril in reducing GLUT2 could be lost as animals re-
ceived higher doses and lower renal ACE was obtained,
because other metabolic routes could provide additional
AII, as previously described in other tissues (36). This
finding points out that low-dose ACE inhibitors provide the
best effect upon renal GLUT2 modulation.
Interestingly, 0.01 mg/kg ramipril, which lowered renal
tissue ACE activity (additively to the diabetes effect), re-
duced cortical renal GLUT1 and GLUT2 content, pointing
to a possible modulation of these glucose transporters by
ACE blockade and/or arterial pressure lowering. In vitro
data suggested an AII modulation of GLUT1 levels in
vascular smooth muscle (19) and in mesangial cells (20),
but no study established the relationship between renal
glucose transporters and AII or arterial pressure lowering
in vivo. We were not able to define if the GLUT1 down-
regulation was caused by the renal ACE inhibition, by the
arterial pressure lowering, or by both, because there was
no non-ACE anti-hypertensive control group, as we could
show before for urinary TGF-β1 in patients with diabetic
nephropathy (37). However, mechanical stretch imposed
by systemic hypertension on glomerular structure can
itself promote overexpression of GLUT1, a mechanism
that involves TGF-β1 signaling activation, suggesting that
lowered arterial pressure levels observed in the present
study may be involved in the observed reduction of GLUT1.
These data reinforce the mechanical stretch role in dia-
betic nephropathy pathogenesis and the importance of
metabolic-hemodynamic interaction. The reduction in the
GLUT1 protein content certainly decreases the cellular
glucose disposal, which contributes to reduction in the
extracellular matrix production. Whether this mechanism
is able to revert established damage or not will depend on
the reversibility of the changes, but it certainly can deceler-
ate the progression of nephropathy.
Albuminuria and urinary TGF-β1 were both clearly
elevated by high arterial pressure associated with hyper-
glycemia, as already described (17), but neither marker
decreased by lowering arterial pressure with an ACE inhib-
itor. We can postulate that the maintenance of very high
glycemia levels continued to stimulate TGF-β1 in mesangi-
al cells, because TGF-β1 is highly stimulated by increased
glucose exposition. Also, it is possible that longer periods
of ACE inhibition could be necessary to disclose benefits
upon albuminuria and urinary TGF-β1 levels, despite the
persistent hyperglycemia. In the same model, 12-week
tight blood pressure control instituted before the develop-
ment of hypertension effectively reduced albuminuria lev-
els and renal fibronectin (38), a protocol clearly different
from ours concerning the beginning before kidney lesion
was started and the longer duration of treatment.
Ramipril is effective in lowering renal tissue ACE activ-
ity and GLUT1 expression in diabetic SHR, an effect prob-
ably mediated by both the renin-angiotensin-system block-
ade and arterial pressure lowering. Moreover, the low dose
of ramipril effectively reduced the renal cortical GLUT2
content to a non-diabetic level, which, surprisingly, was not
observed with the high dose. Further investigation evaluat-
ing longer periods of ACE inhibition, comparison with a
non-ACE inhibitor, and effects of additionally lowering
glycemia is required.
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